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Introduction
Tuberculosis (TB) is an important global infectious disease 
that kills more than 1.2 million people annually1-3. This is 
largely attributed to HIV co-infection4,5 and most important, 
the emergence of  drug-resistant TB6-8. Isoniazid (INH) and 
Rifampicin (RIF) forms the backbone of  the first-line TB 
treatment9. TB that is resistant to both drugs (referred to 
as Multidrug-resistant TB, MDR-TB) is usually associated 
with poor prognosis and increased mortality6,8. More than 
600, 000 cases of  MDR-TB are reported annually3. Genomic 
mutations in Mycobacterium tuberculosis (MTB) mediate 
resistance10-12. More than 96% of  RIF resistant MTB possess 
a genetic mutation in the rpoB gene at codon positions 531, 
526 and 516 located within the 81-bp core region (Rifampicin 
Resistance Determining Region, RRDR) spanning codons 
507-53313-17. The molecular basis of  INH resistance involves 
mutations in more than one gene with the most mutations 
occurring in the katG gene on codon 315 (>70%) and within 
the promoter region of  inhA gene (15-35%)10,18. Mutations 
in the katG gene are relatively more common and usually the 
first to occur18-20. It is estimated that more than 90% of  RIF-
resistant MTB isolates are also resistant to INH, making RIF 
resistance a surrogate marker for MDR-TB diagnosis10,21-24. 
Active surveillance and screening for drug-resistant TB, early 
isolation and management of  confirmed cases are key steps 
in the fight against the spread of  drug-resistant TB1,2. TB 
remains a serious health problem in Malawi25,26. However, 
low levels of  drug-resistant MTB have been reported. A 
2012 phenotypic culture-based large-scale survey in several 
districts of  Malawi indicated MDR-TB levels of  <0.4% 
among new TB cases and 4.8% among previously treated 
patients (J. Mpunga, personal communication, August, 2012). 
While phenotypic studies may still provide useful data, they 
are time-consuming and may be misinterpreted in cases 
where susceptible MTB and resistant MTB co-exist in the 
same patient (Hetero-resistance)27-29. There is currently no 
evidence of  the existence of  transferable genetic elements 
(such as plasmids) between strains of  MTB10,18. Thus, 
indicating that drug resistance in MTB is solely mediated 
by chromosomal mutations and that the presence of  such 
mutations in MTB strains from treatment naïve TB patients 
would indicate a direct person-to-person transmission30. 
In this study, we screened MTB strains isolated from 
treatment naïve pulmonary-TB (PTB) patients living in 
urban Blantyre, Malawi, to determine the occurrence and 
frequency of  genomic mutations that confer resistance to 
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The emergence and spread of  drug-resistant Tuberculosis (TB) is a major public health threat. TB resistance originates in the course 
of  treatment due to genomic mutations in Mycobacterium tuberculosis (MTB). An increase in new cases with drug-resistant TB could be 
an indicator of  high levels of  circulating resistant strains. This study was conducted to determine the occurrence and frequency of  
genomic mutations that mediate Isoniazid (INH) and Rifampicin (RIF) resistance among isolates from untreated TB cases in urban 
Blantyre, Malawi.
Methods
A cross-sectional retrospective study was conducted on a panel of  141(n=141) MTB clinical isolates recovered between June 2010 
and January 2012 from ≥ 2+ Ziehl-Neelsen smear positive new pulmonary-TB patients with no history of  treatment. Frozen isolates 
were revived using the BACTEC MGIT detection system. DNA was extracted using GenoLyse DNA extraction kit and detection of  
genomic mutations was carried out using the GenoType MTBDRplus Ver 2.0 assay.
Results
Out of  the 141 isolates studied, 3 (2.1%) were found carrying mutations in the katG gene that confer resistance to Isoniazid (INH). No 
mutations were detected in the inhA promoter region gene that confer weak INH resistance or in the rpoB gene that confer Rifampicin 
resistance. All katG mutant genes had a S315T1 single point mutation, a genomic alteration that mediates high INH resistance. 
Conclusion
The katG mutant gene conferring resistance to INH was the only genomic mutation observed among the isolates studied and the 
frequency of  occurrence was low. Our findings suggest low levels of  circulating drug-resistant MTB strains in urban Blantyre, Malawi.
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INH and RIF using the GenoTypeMTBDRplus Version 2.0 
The GenoTypeMTBDRplus is a molecular assay designed to 
detect common genetic mutations associated with resistance 
to RIF and INH11,23,31,32.
Materials And Methods
Study isolates
All MTB isolates (n = 159) used in this study were obtained 
from the frozen culture collections of  Dr. Derek Sloan 
from the Malawi Liverpool Wellcome Trust. Isolates were 
recovered from treatment naïve patients with PTB, living in 
urban Blantyre Malawi, between June 2010 and January 2012 
and were identified using Ziehl-Neelsen (Z-N) microscopy at 
Queen Elizabeth Central Hospital (Q.E.C.H) Laboratory in 
Blantyre, Malawi. Specimens with 2+ or 3+ Z-N result were 
cultured in Mycobacterial growth indicator tubes (MGIT) 
on a BACTEC MGIT automated Mycobacterial detection 
system (Becton Dickson, New Jersey, USA) and were stored 
in cryovials at -80oC in 30% glycerol. A fixed sample size of  
159 MTB isolates was the biggest available. 
Ethical Issues
Ethical approval for this study was obtained from the 
University of  Malawi, College of  Medicine Research Ethics 
Committee (COMREC). All MTB clinical isolates were 
numerically coded and delinked from patient identifiers and 
no patient information was accessible. Therefore, informed 
consent was not required for this study.
Reviving frozen Mycobacterium tuberculosis 
isolates
During this study, all frozen isolates were revived and analyzed 
at Malawi Liverpool Wellcome Trust/College of  Medicine 
(MLWT/CoM) TB Research Laboratory at the College 
of  Medicine, Blantyre, Malawi. All specimen handling and 
manipulations were performed in a Class II safety cabinet 
in a Bio-safety level-2 (BSL-2) laboratory. During revival 
process, isolates were thawed at room temperature for one 
hour and then a 0.5 ml aliquot of  the sample was inoculated 
into MGIT, prepared for each isolate by adding 0.8 ml 
oleic acid-albumin-dextrose-catalase (OADC)-PANTA 
(Becton Dickinson, New Jersey, USA). The tubes were then 
incubated at 37°C for 6 - 7 days in an automated BACTEC 
MGIT960 (Becton Dickinson, New Jersey, USA) device 
with continuous monitoring and the time to positivity (TTP) 
was recorded. The isolates were further sub-cultured on a 
nonselective blood agar (BA) media (Trypticase soy agar 
enriched with 5% sheep blood) for 24 - 48 hours to rule out 
contamination and were later stained using the Ziehl Neelsen 
(Z-N) technique to confirm the presence of  characteristic 
coding of  alcohol acid fasting Bacilli (AAFB). Out of  159 
MTB isolates, 18 (11%) were lost to contamination and a 
total of  141 isolates were successfully revived (Table 1).
DNA extraction
DNA extraction was done using GenoLyse DNA extraction 
Kit Ver 1.0 (Hain Lifesciences, Nehren, German) according 
to the manufacturer’s protocol. A total of  1000 µl of  MGIT 
liquid bacterial culture was transferred into a 1.5 ml tube 
and centrifuged for 15 min at 10,000 Xg. The pellet was 
resuspended in 100 µl of  Genolyse and incubated for 5 min 
at 95°C. Subsequently, 100 µl of  neutralization buffer was 
added to the lysate which was vortexed, and centrifuged for 
5 min at full speed. A total of  5 µl supernatant with extracted 
DNA was obtained.
Molecular assay
The GenoTypeMTBDRplus Ver 2.0 (Hain Lifesciences, 
Nehren, Germany) was used to detect MTB drug-resistant 
Table 1: Revived M. tuberculosis isolates (n=159).
Number of M. tuberculosis 
isolates
                 % 
Number revived 159
Pure growth on BA 141 77.47
Pure growth with positive Z-N 
staining
141 100
Lost to contamination 18 11.32
BA, Blood Agar; Z-N, Ziehl Neelsen
Table 2: Detected genomic mutations that confer INH and RIF 





















∇ in all katG MUT
No Mutation detected
inhA 141 ∆ in all inhA WT
∇ in all inhA MUT
No Mutation detected 0
RIF rpoB 141 ∆ in all rpoB WT
∇in all rpoB MUT
No Mutation detected 0
∇, absence of band; ∆, presence of band; MUT, mutant; WT, 
wild-type.
Figure 1: Shows developed GenoTypeMTBDRplus 2.0 strips (Hain 
Lifesciences, German) attached on an interpretation worksheet. 
Lane A: negative control containing amplification mix A and B. 
Lane G:  Negative control containing Genolyse DNA extraction kit. 
Lane 10: katG (MUT 1) genomic mutation indicating a S315T1 
point mutation. No mutations in both rpoB and inhA genes. Lane 
9: Absence of genomic mutations in all the genes. 
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resistance, may vary considerably, even within the same 
country34-36. Such data would be useful clinically and 
epidemiologically. In this study, we found a low number of  
TB drug-resistance related genomic mutations among MTB 
isolates recovered from untreated PTB patients in urban 
Blantyre, Malawi. Mutations were detected only in the katG 
gene and the frequency of  occurrence was very low (2.1%). 
All katG mutations detected were S315T1 (AGC – ACC), a 
serine to threonine single point mutation that mediates high 
INH resistance10,18,20. In this study, no MTB isolates were 
found harboring mutations in the rpoB gene that mediate 
RIF resistance. Whilst RIF resistance due to rpoB mutations 
has widely been reported in other epidemiological studies,37,38 
such were not the findings of  our study. Similarly, we found 
no MTB isolates harboring mutations within the inhA 
promoter region. Unlike katG and rpoB genomic mutations 
that are common, inhA mutations are very rare and are 
usually associated with low-level INH resistance18,39,40. Our 
findings, therefore, suggest that most MTB resistant strains 
circulating in urban Blantyre, Malawi, carry the katG S315T1 
mutation. High prevalence of  INH resistance, attributed 
to katG gene S315T1 mutations has been reported to 
account for a high proportion of  INH resistance in high-
TB-prevalence countries29,41. Another putative katG gene 
mutation (S315T2), a AGC (Ser) - ACA (Thr) point mutation 
that mediates INH resistance, has been sporadically 
reported in other studies42,43. However, this mutation is very 
uncommon and was not observed in this study. Our findings 
generally agree with other epidemiological reports that 
indicate katG gene mutation as relatively more common than 
the other two44,45. No isolates carrying both katG and rpoB 
gene mutations were detected during this study, suggesting a 
very low incidence of  MDR-TB in Blantyre, Malawi.
South Africa (SA) is ranked second as the country with 
the highest drug-resistant TB  cases in the world22,46,47. 
Extensively drug-resistant TB (XDR-TB; MDR plus 
resistance to injectable second-line TB drugs) and pan drug-
resistant TB (PDR-TB; resistant to all available TB drugs) 
have been increasingly reported in SA48-50. This has generated 
concern worldwide, especially in the public health sector of  
neighboring countries including Malawi51,52 because of  high 
risk of  imported drug-resistant MTB strains53,54. Therefore, 
constant monitoring of  resistance related genomic mutations 
in Malawi is relevant especially in persons with presumptive 
TB returning from SA.
Study Limitations
Our study had some limitations. First, as a PCR based 
technique, the GenoTypeMTBDRplus Version 2.0 is 
designed to detect previously described chromosomal 
mutations of  known nucleotide sequences29,33. Therefore, 
rare and novel mutations within or outside the described 
genes are not detected11,55. Second, the data collected and 
analysed in this study is not a representation of  the whole 
community of  Blantyre but rather the urban area only and 
is limited to one hospital (i.e., QECH) and should therefore 
cautiously be generalized. Finally, this was a sub-study and 
a fixed sample size of  bacterial isolates used may not be 
statistically adequate. 
Conclusion
We observed a very low number of  genomic mutations that 
confer resistance among the study isolates, suggesting low 
levels of  circulating MTB resistant strains in urban Blantyre, 
related chromosomal point-mutations within the katG, inhA 
promoter, and rpoB genes. The GenoTypeMTBDRplus 
employs a multiplex PCR during which katG, inhA, rpoB 
genes are amplified using biotin-labeled primers and the 
resulting amplicons are hybridized to DNA probes bound 
to a membrane. During PCR, a total amplification volume 
of  50 µl comprising of  10 µl amplification mix-A, 35 µl 
amplification mix-B and 5 µl template DNA was prepared 
according to the manufacturer’s recommendations.33 The 
amplification protocol was optimized and consisted of  15 
min initial denaturation at 95°C, 10 cycles; 95°C for 30 sec 
and 65°C for 2 min, and then 20 cycles; 95°C for 25 sec, 
50°C for 40 sec, and 70°C for 40 sec, and the final cycle at 
70°C for 8 min. 
Reverse hybridization of  biotin-labeled amplicons to 
membrane-bound probes on the strip was performed 
manually at 45°C using a shaking water bath and this consisted 
of  the addition of  conjugate and substrate to detect visible 
band patterns as recommended by the manufacturer. After 
several washing steps, the membrane-strips were allowed 
to dry. The membrane-bound DNA included the following 
probes: one katG wildtype (WT) probe; two katG mutant 
(MUT) probes (S315T1 and S315T2); four rpoB MUT 
probes (D516V, H526Y, H526D, and S531L); two inhA WT 
probes and four inhA MUT probes (C15T, A16G, T8C, and 
T8A) (Figure 1). All results were interpreted according to 
the manufacturer’s instructions. The absence of  mutation 
was defined as hybridization (indicated by the presence of  a 
colored band) to all the WT probes and no hybridization to 
the MUT probes. The presence of  mutation was defined as 
the absence of  hybridization on any one of  the WT probe, 
with or without hybridization on the corresponding MUT 
probe (Figure 1).
Data analysis
Simple data summaries and descriptive statistics including 
proportions and percentages were used to present the 
occurrence and frequency of  genomic mutations conferring 
resistance to rifampicin or isoniazid or to both drugs among 
the studied MTB isolates.
Results
A total of  141 MTB isolates recovered from treatment naïve 
pulmonary TB patients were screened to determine the 
occurrence and frequency of  genomic mutations within the 
katG, inhA promoter region and rpoB genes. Out of  the 141 
MTB isolates studied, gene mutation was only confirmed for 
the katG gene. No mutations in inhA promoter region and 
rpoB gene were detected in any of  the isolates (Table 2). 
Since no MTB isolate carried both INH and RIF resistant 
genes, no MDR-MTB were detected. As for the frequency 
of  katG genetic mutation, only 3 out of  the 141 MTB (2.1%) 
possessed a katG mutant gene. All katG mutations were 
S315T1, a AGC-to-ACC (Ser →Thr) point mutation (Table 
2). All of  the katG mutations detected at wild-type probes 
were also observed at the corresponding mutant probes. 
Discussion
The emergence of  drug-resistant TB is a major threat to TB 
treatment and eradication. The consequences of  the rise of  
TB drug-resistance in Malawi, a country with a high burden 
of  HIV and poverty, would be extremely devastating. Active 
screening for drug-resistant TB and early management of  
cases is therefore important. The geographical distribution 
of  genomic mutations, that are associated with TB drug-
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Malawi. The characterization and distribution of  specific 
types of  genomic mutations that mediate resistance in 
MTB could be important for optimization of  the diagnosis, 
treatment, and prevention of  drug-resistant TB. Low levels 
of  circulating drug-resistant MTB isolates evidently indicate 
remarkable efforts by the National TB control program in 
the fight against TB in Malawi.
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